Highly commended
Bringing Takeda’s Patient Values to Life in Oncology
With support from akt health
Summary of work
For Takeda, putting patients first is embedded into our culture. But while this is a nice sentiment, it has to be backed by action. At the beginning of 2022, the Takeda EUCAN Oncology Patient Advocacy (PA) team took a long hard look at the challenges still facing the patient community – and what it needed to do to really deliver industry best practice in advocacy relations.
By ensuring we were listening, acting on insight, and always collaborating, we refined our processes and delivered some exceptional content that has directly addressed the priorities of our patient advocacy stakeholders. And at every step we have gone above and beyond to not only track our impact, but ensure that learnings translate into better ways of working.
In short, over the past 18 months the EUCAN Oncology PA team has demonstrated Takeda’s patient-centric culture in action, and laid foundations that will lead to better patient outcomes for years to come.
Judges’ comments
Takeda and akt health have created a well executed and impactful initiative reflective of serious organisational intent. The entry itself was honest, the objectives were clear, the strategy was smart, and the feedback excellent. The panel particularly liked the digital dashboard aspect and thought the method used to measure impact on patients was robust.
